Helps leaders create Global strategies for the worlds of tomorrow
1. Overseas professional consultation
Overseas strategic planning | Analysis Planning Implementation and Optimization
Industry Insight Strategy | Information Collection and Analysis Strategy
Overseas strategic planning：The Six-Step Strategic Planning Model for Going Global to Achieve Overseas Breakthrough Growth.
Industry Insight Strategy：
Industry insights aim to assist clients in gaining a deeper understanding of the current status and future development trends of the local pharmaceutical and medical device industry, and to assist clients in making clear business decisions. We excel in all of this thanks to the strong resource support of Toknow Consulting - Toknow Consulting has more than twenty years of cooperative institutions in various regions, which can better combine and utilize the resources of local cooperative institutions. At the same time, Toknow Consulting also has China's communication logic. Our industry insight customized services cover all aspects of the pharmaceutical and medical device industry.
Toknow Consulting leverages its cooperative institutions in various regions to provide in-depth insights through desk research, exclusive interviews, analysis, and key figures in the pharmaceutical and device industry. We convert scientific data into practical information to help customers estimate market potential and find local partners, and based on the local drug and equipment policy environment, risk assessment, competitive environment, sales channels, marketing models, clinical data, medical organization application scenarios, patient usage evaluation, potential local partners, etc
2. Overseas landing solutions
Efficient implementation and long-term tracking of global network territorial execution
Overseas architecture construction | Compliance hedging profit growth
Local Enterprise Cooperation | Finding the Best Local Business Partner to Quickly Promote Overseas Landing
3. Overseas Financing Solutions
NewCo Solution
Overseas Financing Solutions
Toknow Consulting has established close cooperative relationships with overseas consulting partners, local medical and health venture capital institutions, globally renowned asset management companies, and overseas senior pharmaceutical and equipment investment teams.
Toknow Consulting and its partners have a certain degree of popularity and extensive project resource advantages in the domestic pharmaceutical and medical equipment industry. They have strong scientific research judgment and can identify the most potential and competitive pipeline from numerous projects, find the most suitable overseas institutions/teams (with fast overseas team formation, strong overseas clinical operation capabilities, experience in regulatory approval, and abundant industry resources, etc.), and quickly integrate resources through overseas institutions/teams with strong capital operation capabilities, push up value, and then exit/go public at the appropriate time.
Common overseas financing/transaction models for internationalization of product pipelines:
Mode 1: NewCo
NewCo refers to a new company jointly established by Chinese pharmaceutical companies and capital. Chinese pharmaceutical companies authorize non Greater China equity to overseas new companies, and Chinese pharmaceutical companies invest in the new company with pipeline equity and receive cash, new company equity, and future revenue sharing. This model is particularly suitable for pipelines from Pre IND to Phase IIa clinical trials, with the maximum capital leverage effect. The Newco model bridges the technological value of Chinese assets with the capital operation capabilities of overseas teams.
Mode 2: BD Trading
Overseas partners are responsible for the regional sales, promotion, and commercialization of drugs launched in a certain country or region.
The most common modes are (a) general distribution or distribution; (b) Commercial authorization cooperation.
Mode 3: IP Authorization License
Based on the authorization and licensing of intellectual property (IP) usage rights, both parties cooperate in development, clinical practice, production, and even commercialization.
Common examples include (c) IP Out/in Licensing (Chinese name, IP authorization transaction, technology license transaction, etc.),
(d) R&D Collaboration (Chinese name, cooperative development, strategic cooperation agreement, etc.).
The aforementioned Mode 2 (b) commercial authorization cooperation can also be included in this Mode 3, but it is limited to IP authorization cooperation in the commercial stage.
Mode 4: M&A Mergers and Acquisitions
Acquisition transactions based on the ownership of assets or equity of the target company, including (e) equity acquisitions; (f) Asset acquisition.